Skip to content
Open access

CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity

Aug 2026 · Journal of Experimental Medicine · Vol 223 · 0 citations · 56 references
Medicine

TL;DR

CD1d targeting reshapes tumor immune infiltrates, suppresses tumor growth, and enhances immunotherapy efficacy, suggesting an actionable pathway for therapeutic intervention.

Abstract

Evans et al. identify CD1d as a key regulator of myeloid cell diversity in breast cancer. CD1d targeting reshapes tumor immune infiltrates, suppresses tumor growth, and enhances immunotherapy efficacy, suggesting an actionable pathway for therapeutic intervention.

Read PDF

Similar papers

Open access Sep 2026

TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment

This study provides evidence for a key role of TNFR1, as expressed by malignant cells, in orchestrating a pro-tumor immunosuppressive environment through secondary inflammatory mediators. Results highlight the relevance of interfering TNFα/TNFR1 in cancer immunotherapy.

Elixabet Bolaños, Lorena Cañas-Zabala, Irene Olivera et al. · 0 citations
Aug 2026

Cuproptosis enters the cancer-immunity circuit.

In this issue of Cell, Lei et al. reveal a reciprocal circuit in which cuproptotic tumor cells promote dendritic cell activation and CD8+ T cell priming, whereas T cell-derived IFN-γ sensitizes tumor cells to FDX1-dependent cuproptosis. This self-reinforcing interaction provides a mechanistic rationale for combining cu...

Yun Gao, N. Xing · 1 citation
Aug 2026

Tumor cells recruit macrophage bodyguards to outlast chemotherapy.

In Cell Press Blue, Carvalho et al. identify spatially organized tumor-macrophage niches, EMT-like CD44high cancer cells paired with SPP1/PARP14high macrophages, that drive chemoresistance in bladder cancer. PARP14 inhibition can flip this protective niche into an inflammatory, cisplatin-sensitizing state.

Yuzhao Wang, Zibin Chen, Zhuo-Wei Liu et al. · 0 citations
Aug 2026

CARM1: an epigenetic brake on cDC1-mediated antitumor immunity.

The underlying mechanism of tumor microenvironment-induced dysfunction of conventional type 1 dendritic cells (cDC1) remains unclear. Zhang et al. identify transforming growth factor β-driven coactivator-associated arginine methyltransferase 1 (CARM1) as an epigenetic inhibitor of cDC1 cross-presentation. CARM1 is a ce...

Congliang Chen, Xue-Tao Cao · 0 citations
Aug 2026

TREM1 Blockade Reprograms Tumor‐Associated Macrophages and Improves Anti‐PD‐1 Efficacy in Gastric Cancer

The objective response rate of immune checkpoint inhibitors in patients with gastric cancer is limited. Targeting specific subtypes of macrophages holds promise for expanding the potential population sensitive to immune checkpoint inhibitors. This study aims to evaluate the key role of TREM1+tumor‐associated macrophage...

Jin-Nan Chen, Tianwei Xu, Chao Lin · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.